Activin A Receptor, Type IIA (ACVR2A) (N-Term) antibody

Antigen: Activin A Receptor, Type IIA (ACVR2A)

Synonyms: ACVR2, ACTRII, Acvr2, ActrIIa, TactrII, rActR-II, ACVR2A, acvr2a, acvr2, actr2a, wu:fa02e10, actrii

Binding Site: N-Term

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Conjugate: Un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Certificates: ISO 9001:2008

Catalog no.: ABIN391160

Additional Information

Alternative name: ACVR2A

Gene ID: 92

UniProt: P27037

Immunogen: This ACVR2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human ACVR2A.

Isotype: Ig

Description: Other names: Activin receptor type-2A [Precursor], Activin receptor type IIA, ACTR-IIA, ACTRIIA, ACVR2

Characteristics: Purified Rabbit Polyclonal Antibody (Pab)

Specificity: This ACVR2A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human ACVR2A.

Molecular Weight: 57639 DA

Comments:

Background: ACVR2A is an activin A type II receptor. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases.

Application Details

Application Notes: The suggested dilution is: ELISA~~1:1,000 Western blotting~~1:100~500 Immunohistochemistry~~1:50~100

Concentration: 0.25 mg/ml

Purification: Purified

Buffer: Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage: Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles

Research Area: Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cell Structure, Cell Cycle

Restrictions: For Research Use only

Images

Western blot analysis of anti-ACVR2A Antibody (N-term) (ABIN391160) in mouse liver brain and kidney tissue lysates (35ug/lane). ACVR2A (arrow) was detected using the purified Pab.

Western blot analysis of ACVR2A (arrow) using rabbit polyclonal ACVR2A Antibody (N-term) (ABIN391160). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the ACVR2A gene (Lane 2) (Origene Technologies).

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry. clinical relevance has not been evaluated. BC = breast carcinoma. HC = hepatocarcinoma.

Publications

Product: Casagrandi, Bearfield, Geary et al.: "Inhibin, activin, follistatin, activin receptors and beta-glycan gene expression in the placental tissue of patients with pre-eclampsia." in: Molecular human reproduction, Vol. 9, Issue 4, pp. 199-203, 2003 (PubMed).

Greenwald, Groppe, Gray et al.: "The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly." in: Molecular cell, Vol. 11, Issue 3, pp. 605-17, 2003 (PubMed).

Olaru, Mori, Yin et al.: "Loss of heterozygosity and mutational analyses of the ACTRII gene locus in human colorectal tumors." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 83, Issue 12, pp. 1867-71, 2003 (PubMed).